Dr. Buzdar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of Texas Health Science Center at HoustonFellowship, Medical Oncology, 1974 - 1975- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1974 - 1975
Norwalk Hospital/Yale UniversityResidency, Internal Medicine, 1972 - 1973
The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine, 1971 - 1972
Lakewood HospitalResidency, Internal Medicine, 1970 - 1971
Old Dominion UniversityResidency, Internal Medicine, 1969 - 1970- Kuakini Medical CenterInternship, Transitional Year, 1968 - 1969
Nishtar Medical CollegeClass of 1967
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2027
GA State Medical License 2023 - 2027
TN State Medical License 2023 - 2027
TX State Medical License 1975 - 2027
LA State Medical License 2023 - 2026
OK State Medical License 2020 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer Start of enrollment: 2001 Apr 01
- Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer Start of enrollment: 2002 Nov 01
- Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2007 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsMolecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.Clinton Yam, Nour Abuhadra, Ryan Sun, Beatriz E Adrada, Qing-Qing Ding
Clinical Cancer Research. 2022-07-01 - 2 citationsSingle-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.James N. Ingle, Krishna R. Kalari, Poulami Barman, Lois E. Shepherd, Matthew J. Ellis
Pharmacogenetics and Genomics. 2021-01-01 - 16 citationsPharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole actionJunmei Cairns, James N. Ingle, Tanda M. Dudenkov, Krishna R. Kalari, Erin E. Carlson
JCI Insight. 2020-08-20
Press Mentions
16-Year Survivor: A Breast Cancer Diagnosis Helped Me Find My Life’s PurposeNovember 25th, 2019
HER2-Positive Breast Cancer Study Finds New Option to Avoid Cardiac ToxicitySeptember 7th, 2018
Clinical Trial Finds Concurrent Therapy Not Necessary to Achieve High Pathological Complete Responses in Breast Cancer Patients with HER-2-Positive DiseaseFebruary 10th, 2016- Join now to see all
Professional Memberships
- Member
Other Languages
- Hindi, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
